This article discusses Mycobacterium avium complex pulmonary disease (MAC-PD), a chronic and recurrent infection that poses significant challenges in clinical management due to its high recurrence rate. The key clinical dilemma is distinguishing between true recurrence, caused by the persistence of existing MAC strains, and reinfection with new strains. This distinction is crucial for guiding appropriate treatment strategies and improving patient outcomes. The article emphasizes the importance of genotypic strategies, such as molecular typing, to accurately identify the causative strain and differentiate between these two scenarios, thereby supporting informed clinical decision-making for patients with MAC-PD.
Key note: Genotypic strategies are essential for differentiating MAC-PD recurrence from reinfection to guide effective treatment.